Ketorolac 0.45% Ophthalmic Solution

  title={Ketorolac 0.45\% Ophthalmic Solution},
  author={Paul L. McCormack},
  journal={Drugs \& Aging},
Ketorolac 0.45% ophthalmic solution is a topical NSAID indicated in the US for the treatment of ocular pain and inflammation following cataract surgery.In animal studies, the ocular relative bioavailability of single-dose topical ketorolac 0.45% ophthalmic solution was 2- to 3-fold higher than that of ketorolac 0.4% ophthalmic solution.In two identically designed, randomized, double-masked, multicentre trials in adult patients undergoing cataract extraction, the proportions of patients with a… 
Artificial tears alone versus 0.45% ketorolac tromethamine with artificial tears for the treatment of acute viral conjunctivitis.
The findings indicate that 0.45% ketorolac tromethamine was not superior to the use of artificial tears in relieving the signs and symptoms of viral conjunctivitis.
Loteprednol etabonate ophthalmic suspension 0.5 %: efficacy and safety for postoperative anti-inflammatory use
The available clinical data suggest that loteprednol etabonate is an efficacious and safe corticosteroid for the treatment of postoperative inflammation.
Intranasal Ketorolac
In adult patients with acute pain following major surgery, intranasal ketorolac 31.5mg three or four times daily for ≤5 days was generally well tolerated and most adverse events in clinical trials were considered to be of mild severity and transient in nature.
Ketorolac Tromethamine Spray Prevents Postendotracheal-Intubation-Induced Sore Throat after General Anesthesia
It is demonstrated that preanesthesia 5% ketorolac tromethamine spray could effectively decrease postendotracheal-intubation-induced sore throat in patients undergoing general anesthesia.
Comparing the Efficacy of Ophthalmic NSAIDs in Common Indications
Objective: To review the commercially available ophthalmic nonsteroidal anti-inflammatory drugs (NSAIDs), identify opportunities for therapeutic substitutions within and outside of their Food and
Topical Mucoadhesive Alginate-Based Hydrogel Loading Ketorolac for Pain Management after Pharmacotherapy, Ablation, or Surgical Removal in Condyloma Acuminata
Kentorolac hydrogel showed 53% anti-inflammatory activity, suggesting that it is a stable and suitable formulation for the treatment of inflammatory processes, such as those occurring upon chemical or surgical removal of anogenital warts.
Current options and emerging therapies for anterior ocular inflammatory disease
Several promising modalities for AOID, particularly for allergic conjunctivitis, immune treatments for uveitis and dry eye syndrome are in late-stage development that could offer optimal treatment paradigm once available in the clinic.
Pharmacological Interventions for Post-operative Sore Throat (POST): A Network Meta-analysis
Ketorolac tromethamine was the most effective and significantly better than all other treatments in reducing POST rates, and the following treatments were found to be significantly effective in reducingPOST.
Diabetic retinopathy: a complex pathophysiology requiring novel therapeutic strategies
Improvements in knowledge of the condition facilitate therapeutic innovations that continue to address unmet medical need and improve patient outcomes, with a focus on the development of targeted medicines.
Non-steroidal anti-inflammatory drugs ( NSAIDs ) in ophthalmology : pharmacological and clinical characteristics
Therapeutic indications may differ slightly between individual drugs, but generally they include prevention and treatment of cystoid macular edema after cataracts surgery, inhibition of intra-operative miosis during cataract surgery, reduction of pain and photophobia after refractive surgery, and, in addition, treatment of allergic conjunctivitis.


An update on the use of ophthalmic ketorolac tromethamine 0.4%
Ketorolac tromethamine 0.4% ophthalmic solution is indicated for the reduction of ocular pain and burning/stinging following cataract and refractive surgery and effectively treats cystoids macular oedema, inhibits miosis and may prevent cystoid macular Oedema when used both pre- and postoperatively.
A review of the use of ketorolac tromethamine 0.4% in the treatment of post-surgical inflammation following cataract and refractive surgery
The purpose of this paper is to review the use of ketorolac tromethamine 0.4% in the treatment of post-surgical inflammation following cataract and refractive surgery.
Ex vivo corneal epithelial wound healing following exposure to ophthalmic nonsteroidal anti-inflammatory drugs
Corneas treated with ketorolac 0.45% healed as rapidly as those treated with MEM, likely secondary to addition of CMC and removal of BAK.
Ocular pharmacokinetics of 0.45% ketorolac tromethamine
The CMC-containing formulation of 0.45% ketorolac, pH 6.8, increased ket orolac bioavailability by 2-fold in aqueous humor and by 3- fold in iris-ciliary body in comparison to the prior formulation, 0.4%, allowing a reduced dosing schedule from 4 times daily to twice daily.